This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Invest In Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 technology and international expansion of the Control-IQ technology add to the company's solid second-quarter performance.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.
Here's Why You Should Retain PacBio (PACB) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about PacBio (PACB) owing to its slew of strategic deals and strength in its Sequel system.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and raised 2021 outlook.
Petco (WOOF) Q2 Earnings Beat on Continued Demand for Pet Care
by Zacks Equity Research
Petco (WOOF) Q2 earnings exceed estimates on buoyant demand for pet care products and services.
Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.
Abiomed's (ABMD) Impella ECP Gets FDA's Breakthrough Device Tag
by Zacks Equity Research
Abiomed's (ABMD) Impella ECP is likely to offer critical hemodynamic support to a wider pool of coronary artery disease patients.
West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about West Pharmaceutical's (WST) robust proprietary products segment and its continued strength in R&D.
Masimo (MASI) Bridge Hailed as Opioid Substitute in New Study
by Zacks Equity Research
Masimo's (MASI) Bridge device is likely to allow more patients to be benefited by auriculotherapy, thereby reducing the possibility of opioid overuse.
ResMed (RMD) Hits New 52-Week High: What's Behind the Rally?
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) potential in digital health and its strong emphasis on product development.
Teleflex (TFX) Rides on UroLift Growth, Hurt by Pandemic Woes
by Zacks Equity Research
Teleflex (TFX) has decided to increase its investment in 2021 and run a national campaign for the full year.
Globus Medical (GMED) Gets FDA Nod for Excelsius3D
by Zacks Equity Research
The receipt of FDA's 510(k) clearance for Globus Medical's (GMED) Excelsius3D is expected to expand the company's presence in the intraoperative imaging system space.
Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev
by Zacks Equity Research
Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.
Time to Focus on IDEXX Laboratories (IDXX) for Strong Earnings Growth Potential
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider IDEXX Laboratories (IDXX).
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.
BD's (BDX) New Offering to Boost Labs' Flow Cytometry Abilities
by Zacks Equity Research
BD's (BDX) latest product offering is expected to help improve access to instrumentation for complex scientific research to more laboratories.
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
by Zacks Equity Research
Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.
Amedisys (AMED) Suffers From Low Occupancy Amid Pandemic
by Zacks Equity Research
The prolonged and lingering impact of COVID-19 on Amedisys (AMED) Hospice business has hampered its ability to grow at the earlier-projected rates.
Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the four reported business segments is driving the top line for Thermo Fisher (TMO).
Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio
by Zacks Equity Research
Strong performance by the Dental, Medical & Technology and Value-Added Services segments is driving Henry Schein's (HSIC) top line.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
3 Medical Instruments Stocks Countering Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on base business recovery. ISRG, IDXX and ALC are set to gain the most. However, falling demand for COVID-19 tests might disrupt the trend.
IDEXX (IDXX) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses drove IDEXX's (IDXX) second-quarter revenues.
Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 16.42% and 5.72%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?